What is LOPJLB’s current signal on ANNX?

LOPJLB’s latest quantitative signal on Annexon, Inc. (ANNX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is ANNX in?

Annexon, Inc. (ANNX) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Annexon, Inc. (ANNX) do?

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those s…

Annexon, Inc. (ANNX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$3.67-4.18%Close

SELLCRISIS · day 1

[SCORES & PROFILE]

FUND: 12
VALUE: 8
GROWTH: 45
GARP: 6
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-63.7%

REV YoY-

ROE-106.2%

EPS YoY-

ROA-82.4%

GROSS

NET

[VALUATION]

P/E TTM-3.16

P/E FWD-

SECTOR PE20.48

INDUSTRY PE13.99

P/B3.96

P/FCF-

EV/EBITDA-2.13

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E13.25

ALTMAN Z-

CURR RATIO5.53

ND/EBITDA-

BETA1.33

FAQ

What is LOPJLB’s current signal on ANNX?: LOPJLB’s latest quantitative signal on Annexon, Inc. (ANNX) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is ANNX in?: Annexon, Inc. (ANNX) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Annexon, Inc. (ANNX) do?: Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those s…

Annexon, Inc. (ANNX)

Key stats

Industry peers

Prediction markets

FUNDAMENTALS

Company news

FAQ